JP6997627B2 - Ｃｄｋ９阻害剤としての多環式アミド誘導体 - Google Patents

Ｃｄｋ９阻害剤としての多環式アミド誘導体 Download PDF

Info

Publication number
JP6997627B2
JP6997627B2 JP2017567737A JP2017567737A JP6997627B2 JP 6997627 B2 JP6997627 B2 JP 6997627B2 JP 2017567737 A JP2017567737 A JP 2017567737A JP 2017567737 A JP2017567737 A JP 2017567737A JP 6997627 B2 JP6997627 B2 JP 6997627B2
Authority
JP
Japan
Prior art keywords
pyridine
chloro
cyclohexanecarboxamide
dihydro
acetamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017567737A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018522869A (ja
JP2018522869A5 (cg-RX-API-DMAC10.html
Inventor
カート・ゴードン・パイク
ベルナール・クリストフ・バルラーム
ジャネット・ホーキンス
クリストファー・デ・サビ
メリッサ・メアリー・バズビンダー
アレクサンダー・ハード
ミッシェル・ラム
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of JP2018522869A publication Critical patent/JP2018522869A/ja
Publication of JP2018522869A5 publication Critical patent/JP2018522869A5/ja
Application granted granted Critical
Publication of JP6997627B2 publication Critical patent/JP6997627B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Detergent Compositions (AREA)
  • Polyesters Or Polycarbonates (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
JP2017567737A 2015-06-29 2016-06-27 Ｃｄｋ９阻害剤としての多環式アミド誘導体 Active JP6997627B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562185852P 2015-06-29 2015-06-29
US62/185,852 2015-06-29
PCT/EP2016/064899 WO2017001354A1 (en) 2015-06-29 2016-06-27 Polycyclic amide derivatives as cdk9 inhibitors

Publications (3)

Publication Number Publication Date
JP2018522869A JP2018522869A (ja) 2018-08-16
JP2018522869A5 JP2018522869A5 (cg-RX-API-DMAC10.html) 2019-07-18
JP6997627B2 true JP6997627B2 (ja) 2022-01-17

Family

ID=56292699

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017567737A Active JP6997627B2 (ja) 2015-06-29 2016-06-27 Ｃｄｋ９阻害剤としての多環式アミド誘導体

Country Status (38)

Country Link
US (4) US9845331B2 (cg-RX-API-DMAC10.html)
EP (2) EP3539961B1 (cg-RX-API-DMAC10.html)
JP (1) JP6997627B2 (cg-RX-API-DMAC10.html)
KR (1) KR102663113B1 (cg-RX-API-DMAC10.html)
CN (1) CN107873028B (cg-RX-API-DMAC10.html)
AR (1) AR105179A1 (cg-RX-API-DMAC10.html)
AU (1) AU2016286200B2 (cg-RX-API-DMAC10.html)
BR (1) BR122019013677B1 (cg-RX-API-DMAC10.html)
CA (1) CA2989499C (cg-RX-API-DMAC10.html)
CL (1) CL2017003306A1 (cg-RX-API-DMAC10.html)
CO (1) CO2017013713A2 (cg-RX-API-DMAC10.html)
CR (2) CR20170596A (cg-RX-API-DMAC10.html)
CY (2) CY1122111T1 (cg-RX-API-DMAC10.html)
DK (2) DK3313838T3 (cg-RX-API-DMAC10.html)
DO (2) DOP2017000295A (cg-RX-API-DMAC10.html)
EA (1) EA035383B1 (cg-RX-API-DMAC10.html)
ES (2) ES2902148T3 (cg-RX-API-DMAC10.html)
HR (2) HRP20211970T1 (cg-RX-API-DMAC10.html)
HU (2) HUE057343T2 (cg-RX-API-DMAC10.html)
IL (1) IL256393B (cg-RX-API-DMAC10.html)
LT (2) LT3313838T (cg-RX-API-DMAC10.html)
ME (1) ME03404B (cg-RX-API-DMAC10.html)
MX (1) MX371034B (cg-RX-API-DMAC10.html)
MY (1) MY201673A (cg-RX-API-DMAC10.html)
NI (1) NI201700174A (cg-RX-API-DMAC10.html)
PE (1) PE20180530A1 (cg-RX-API-DMAC10.html)
PH (1) PH12017502334B1 (cg-RX-API-DMAC10.html)
PL (2) PL3313838T3 (cg-RX-API-DMAC10.html)
PT (2) PT3313838T (cg-RX-API-DMAC10.html)
RS (2) RS58712B1 (cg-RX-API-DMAC10.html)
SI (2) SI3313838T1 (cg-RX-API-DMAC10.html)
SM (2) SMT202200005T1 (cg-RX-API-DMAC10.html)
SV (1) SV2017005598A (cg-RX-API-DMAC10.html)
TN (1) TN2017000486A1 (cg-RX-API-DMAC10.html)
TR (1) TR201909286T4 (cg-RX-API-DMAC10.html)
TW (1) TWI723028B (cg-RX-API-DMAC10.html)
WO (1) WO2017001354A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201800563B (cg-RX-API-DMAC10.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018335617B2 (en) 2017-09-25 2021-12-09 Astrazeneca Ab Combination of a BTK inhibitor and an inhibitor of CDK9 to treat cancer
US11319295B2 (en) 2017-10-09 2022-05-03 Merck Sharp & Dohme Corp. Substituted phenyloxetane and phenyltetrahydrofuran compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors
CN108129288B (zh) * 2017-12-27 2021-01-22 上海毕得医药科技股份有限公司 一种反式-3-羟基环丁基甲酸的合成方法
TWI810397B (zh) 2018-11-14 2023-08-01 瑞典商阿斯特捷利康公司 治療癌症之方法
CN114008046B (zh) * 2019-06-27 2023-08-18 南京明德新药研发有限公司 作为cdk9抑制剂的氮杂吲哚连吡唑类化合物
AU2020345950A1 (en) 2019-09-11 2022-03-31 Prelude Therapeutics Incorporated CDK inhibitors and their use as pharmaceuticals
AU2020401999B2 (en) * 2019-12-09 2024-01-18 Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. Compound as cyclin-dependent kinase 9 inhibitor and use thereof
JP7451765B2 (ja) * 2020-05-12 2024-03-18 蘇州阿尓脈生物科技有限公司 Ｃｄｋ阻害剤としてのピリジンアセトアミド系誘導体、その調製方法及び用途
EP4141004A4 (en) * 2020-05-12 2023-08-23 Suzhou Alphama Biotechnology Co., Ltd. POLYCYCLIC AMIDE DERIVATIVE SERVING AS A CDK9 INHIBITOR, METHOD FOR PREPARING IT AND ITS USE
CN116615248A (zh) 2020-06-24 2023-08-18 阿斯利康(英国)有限公司 抗体-药物缀合物和cdk9抑制剂的组合
EP4194450A4 (en) 2020-08-07 2024-10-30 Pharmablock Sciences (Nanjing), Inc. CDK9 INHIBITOR AND USE THEREOF
TWI809330B (zh) * 2020-11-20 2023-07-21 大陸商勁方醫藥科技(上海)有限公司 Cdk9抑制劑的多晶型物及其製法和用途
CN115381824B (zh) * 2021-05-24 2024-11-05 石药集团中奇制药技术（石家庄）有限公司 周期蛋白依赖性激酶9抑制剂的用途
WO2022247785A1 (zh) * 2021-05-24 2022-12-01 石药集团中奇制药技术（石家庄）有限公司 一种周期蛋白依赖性激酶9抑制剂的用途
CN117813289A (zh) * 2021-07-14 2024-04-02 上海海雁医药科技有限公司 吡唑衍生物及其中间体和制备方法
CN115703738B (zh) * 2021-08-16 2024-06-21 中国科学院上海药物研究所 含2-芳杂环取代的脲类化合物、其制备方法和用途
CN118613257A (zh) * 2021-12-23 2024-09-06 鲁汶大学 用于抑制yap/taz-tead的四氢吡唑并嘧啶及相关类似物
CA3251059A1 (en) 2022-05-02 2023-11-09 The Board Of Trustees Of The Leland Stanford Junior University Compositions, systems and methods for modulating a target gene
WO2024039210A1 (ko) 2022-08-17 2024-02-22 한국화학연구원 Cdk2 및/또는 cdk9의 억제 또는 분해용 화합물 및 이들의 의약 용도
CN117659022A (zh) * 2022-09-06 2024-03-08 苏州阿尔脉生物科技有限公司 脲基取代吡啶类化合物、包含其的药物组合物及其医药用途
WO2024220876A1 (en) * 2023-04-19 2024-10-24 Alcon Inc. N-substituted c6 cyclyl carboxamide compounds and uses thereof
WO2025076115A1 (en) * 2023-10-02 2025-04-10 Prelude Therapeutics Incorporated Cdk inhibitors and their use as pharmaceuticals
WO2026024933A1 (en) * 2024-07-24 2026-01-29 Prelude Therapeutics Incorporated Cdk inhibitors and their use as pharmaceuticals

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008133192A1 (ja) 2007-04-19 2008-11-06 Takeda Pharmaceutical Company Limited 縮合イミダゾール化合物およびその用途
WO2011101640A1 (en) 2010-02-19 2011-08-25 Medical Research Council Technology Fused heterocyclic compounds for use in the treatment of malaria
WO2011124539A1 (de) 2010-04-07 2011-10-13 Bayer Cropscience Ag Bicyclische pyridinylpyrazole
WO2012101063A1 (en) 2011-01-28 2012-08-02 Novartis Ag N-acyl pyridine biaryl compounds and their uses
WO2013050434A1 (en) 2011-10-06 2013-04-11 Bayer Intellectual Property Gmbh Heterocyclylpyri(mi)dinylpyrazole
WO2014160017A1 (en) 2013-03-13 2014-10-02 Abbvie Inc. Pyridine cdk9 kinase inhibitors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5379787B2 (ja) 2007-04-24 2013-12-25 インゲニウム ファーマシューティカルズ ジーエムビーエイチ プロテインキナーゼの阻害剤
EP2137166B1 (en) 2007-04-24 2012-05-30 Ingenium Pharmaceuticals GmbH 4, 6-disubstituted aminopyrimidine derivatives as inhibitors of protein kinases
ES2539518T3 (es) 2007-04-24 2015-07-01 Astrazeneca Ab Inhibidores de proteínas quinasas
US8389521B2 (en) 2007-04-24 2013-03-05 Ingenium Pharmaceuticals Gmbh Inhibitors of protein kinases
WO2008132138A1 (en) 2007-04-25 2008-11-06 Ingenium Pharmaceuticals Gmbh Derivatives of 4,6-disubstituted aminopyrimidines
AU2008309517B2 (en) 2007-10-12 2013-03-14 Astrazeneca Ab Inhibitors of protein kinases
KR20120049940A (ko) * 2009-09-04 2012-05-17 노파르티스 아게 키나제 억제제로서의 헤테로아릴 화합물
US20110113038A1 (en) 2009-11-12 2011-05-12 International Business Machines Corporation Search term security
EA201201274A1 (ru) 2010-03-10 2013-04-30 Инджениум Фармасьютиклз Гмбх Ингибиторы протеинкиназ
WO2012066065A1 (en) 2010-11-17 2012-05-24 Novartis Ag Phenyl-heteroaryl amine compounds and their uses
WO2012101062A1 (en) * 2011-01-28 2012-08-02 Novartis Ag Substituted bi-heteroaryl compounds as cdk9 inhibitors and their uses
WO2012101064A1 (en) * 2011-01-28 2012-08-02 Novartis Ag N-acyl pyrimidine biaryl compounds as protein kinase inhibitors
JP2016512559A (ja) 2013-03-13 2016-04-28 アッヴィ・インコーポレイテッド Ｃｄｋ９キナーゼ阻害薬
TW201446763A (zh) 2013-03-14 2014-12-16 Abbvie Inc 吡咯并［２，３－ｂ］吡啶ｃｄｋ９激酶抑制劑
CN105189512A (zh) 2013-03-14 2015-12-23 艾伯维公司 吡咯并嘧啶cdk9激酶抑制剂

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008133192A1 (ja) 2007-04-19 2008-11-06 Takeda Pharmaceutical Company Limited 縮合イミダゾール化合物およびその用途
WO2011101640A1 (en) 2010-02-19 2011-08-25 Medical Research Council Technology Fused heterocyclic compounds for use in the treatment of malaria
WO2011124539A1 (de) 2010-04-07 2011-10-13 Bayer Cropscience Ag Bicyclische pyridinylpyrazole
WO2012101063A1 (en) 2011-01-28 2012-08-02 Novartis Ag N-acyl pyridine biaryl compounds and their uses
WO2013050434A1 (en) 2011-10-06 2013-04-11 Bayer Intellectual Property Gmbh Heterocyclylpyri(mi)dinylpyrazole
WO2014160017A1 (en) 2013-03-13 2014-10-02 Abbvie Inc. Pyridine cdk9 kinase inhibitors

Also Published As

Publication number Publication date
RS62781B1 (sr) 2022-01-31
LT3539961T (lt) 2021-12-27
CL2017003306A1 (es) 2018-06-29
ES2728356T3 (es) 2019-10-23
TW201718573A (zh) 2017-06-01
HUE057343T2 (hu) 2022-05-28
EA035383B1 (ru) 2020-06-04
EP3313838A1 (en) 2018-05-02
IL256393B (en) 2021-12-01
LT3313838T (lt) 2019-06-10
JP2018522869A (ja) 2018-08-16
AU2016286200B2 (en) 2018-10-04
KR20180021830A (ko) 2018-03-05
HRP20211970T1 (hr) 2022-03-18
SI3539961T1 (sl) 2022-02-28
HRP20190748T1 (hr) 2019-06-14
PE20180530A1 (es) 2018-03-19
MY201673A (en) 2024-03-12
DK3313838T3 (da) 2019-06-11
DOP2017000295A (es) 2017-12-31
US20210171541A1 (en) 2021-06-10
US10717746B2 (en) 2020-07-21
DOP2018000207A (es) 2018-10-15
EP3539961B1 (en) 2021-10-06
ES2902148T3 (es) 2022-03-25
PH12017502334B1 (en) 2023-05-26
ME03404B (me) 2020-01-20
CR20210297A (es) 2021-09-29
EA201890094A1 (ru) 2018-07-31
EP3313838B1 (en) 2019-04-03
BR112017027394A2 (pt) 2018-11-06
PL3313838T3 (pl) 2019-08-30
WO2017001354A1 (en) 2017-01-05
TWI723028B (zh) 2021-04-01
EP3539961A1 (en) 2019-09-18
CN107873028A (zh) 2018-04-03
HUE043440T2 (hu) 2019-08-28
CY1125066T1 (el) 2023-03-24
US20220340592A1 (en) 2022-10-27
CR20170596A (es) 2018-07-04
CN107873028B (zh) 2021-02-02
MX2017016244A (es) 2018-04-20
SV2017005598A (es) 2018-02-23
US9845331B2 (en) 2017-12-19
SMT202200005T1 (it) 2022-03-21
BR122019013677B1 (pt) 2024-01-02
PT3313838T (pt) 2019-06-24
US20180093998A1 (en) 2018-04-05
AR105179A1 (es) 2017-09-13
SMT201900298T1 (it) 2019-07-11
TR201909286T4 (tr) 2019-07-22
CO2017013713A2 (es) 2018-03-28
ZA201800563B (en) 2022-08-31
IL256393A (en) 2018-02-28
MX371034B (es) 2020-01-13
DK3539961T3 (da) 2022-01-03
US11352369B2 (en) 2022-06-07
CY1122111T1 (el) 2020-11-25
US20160376287A1 (en) 2016-12-29
CA2989499A1 (en) 2017-01-05
AU2016286200A1 (en) 2018-02-08
RS58712B1 (sr) 2019-06-28
CA2989499C (en) 2023-10-31
KR102663113B1 (ko) 2024-05-02
SI3313838T1 (sl) 2019-06-28
PH12017502334A1 (en) 2018-06-25
PT3539961T (pt) 2021-12-20
NI201700174A (es) 2018-10-19
TN2017000486A1 (en) 2019-04-12
PL3539961T3 (pl) 2022-02-14

Similar Documents

Publication Publication Date Title
US11352369B2 (en) Pyridine and pyrimidine derivatives
KR102388208B1 (ko) 암을 치료하기 위한 거대 환형 mcl1 억제제
TW202246255A (zh) Ｃｄｋ抑制劑及其使用方法
JP6371430B2 (ja) ブロモドメイン阻害薬
TW202128685A (zh) 作為ｆｇｆｒ抑制劑之雙環雜環
EP3288931B2 (en) Certain protein kinase inhibitor
KR20140096100A (ko) 이환 피페라진 화합물
US20230339977A1 (en) Substituted heteroaryl compound, and composition and application thereof
JP2021102619A (ja) ブロモドメイン阻害剤
HK40014442A (en) Polycyclic amide derivatives as cdk9 inhibitors
HK40014442B (en) Polycyclic amide derivatives as cdk9 inhibitors
HK1250985A1 (en) Polycyclic amide derivatives as cdk9 inhibitors
HK1250985B (en) Polycyclic amide derivatives as cdk9 inhibitors
BR112017027394B1 (pt) Composto, forma cristalina, composição farmacêutica e uso do mesmo
CN120265629A (zh) 被取代的双环和三环hset抑制剂

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190613

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190613

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200528

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200602

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200901

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210216

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210420

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210715

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210813

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20211130

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20211217

R150 Certificate of patent or registration of utility model

Ref document number: 6997627

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250